Chronic Kidney Disease amongst Sickle Cell Anaemia Patients at the University of Maiduguri Teaching Hospital, Northeastern Nigeria: A Study of Prevalence and Risk Factors

A.A. Bukar1, M.M. Sulaiman2, A.I. Ladu1, A.M. Abba1, M.K. Ahmed1, G.T. Marama1 and U.M. Abjah1.

1 Department of Haematology University of Maiduguri. P.M.B 1069, Maiduguri Nigeria.
2 Department of Medicine (nephrology unit) University of Maiduguri. P.M.B 1069, Maiduguri Nigeria.

Abstract. Background: Involvement of the kidneys in patients with sickle cell anaemia is a well recognised chronic complication. This study seeks to determine the prevalence of chronic kidney disease in patients with homozygous sickle cell disease (HbSS) and to identify risk factors associated with its development.

Methodology: The subjects consisted of adolescents and adults with HbSS recruited sequentially from the adult haematology outpatient clinic and Daycare ward of the unit. Clinical variables including age at diagnosis of SCA, the frequency of vaso-occlusive crisis and transfusion therapy, as well as laboratory data including haematological profile and renal function tests were obtained. The glomerular filtration rate was estimated (eGFR) using the ‘modification of diet in renal disease’ (MDRD) formula.

Results: Two hundred and eighty-four HbSS patients were recruited. The prevalence of CKD amongst them was 38.9%. Further stratification of the patients based on eGFR showed that sixty-nine (26.8%) had hyperfiltration; 35 (13.6%) stage 1 CKD; 53 (20.6%) stage 2 CKD; 33 (12.8%) stage 3a CKD; 28 (10.9%) stage 3b CKD; 30 (11.7%) stage 4 CKD and 9 (3.5%) had end stage renal disease. There was significant association between eGFR and clinical parameters such as age (r -0.353, p=0.000), SBP (r -0.148, p=0.021), DBP (r -0.213, p=0.001) and total number of blood received (r -0.276, p=0.000); and laboratory parameters such as PCV (r 0.371, p=0.000); urea (r 0.527, p=0.000), creatinine (r 0.625, p=0.000) and uric acid (r -0.419, p=0.000).

Conclusions: The present study has revealed a high prevalence of CKD amongst patients with SCA in our region. Clinical and laboratory predictors of CKD using eGFR were identified to include age, SBP, number of units of blood transfusion, PCV, urea, creatinine and uric acid levels.

Keywords: Sickle cell anaemia, Kidney disease, Nigeria.

Citation: Bukar A.A., Sulaiman M.M., Ladu A.I., Abba A.M., Ahmed M.K., Marama G.T., Abjah U.M. Chronic kidney disease amongst sickle cell anaemia patients at the University of Maiduguri teaching hospital, northeastern Nigeria: a study of prevalence and risk factors. Mediterr J Hematol Infect Dis 2019, 11(1): e2019010, DOI: http://dx.doi.org/10.4084/MJHID.2019.010

Published: January 1, 2019 Received: June 5, 2018 Accepted: November 26, 2018

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Correspondence to: Dr A.I. Ladu Department of Haematology, College of Medical Sciences, University of Maiduguri, P.M.B D1069. Maiduguri, Nigeria. Email: adamaisahladu@gmail.com

Introduction. Homozygous sickle cell disease (HbSS) is an inherited disorder of haemoglobin resulting from single nucleotide change i.e. substitution of thymine for adenine in the sixth codon of the beta globin-chain gene, this causes coding of amino acid valine instead of glutamate in position 6 of the beta-globin chain resulting in formation of an abnormal haemoglobin termed haemoglobin S (HbS).1 The haemoglobin S derived
from this mutation forms polymers if it undergoes deoxygenation; this polymerisation is the primary though not the exclusive cause of the clinical manifestation of sickle cell anaemia (SCA). The net effects of polymerized haemoglobin are membrane damage, cell dehydration and altered rheology with resulting chronic haemolysis and vaso-occlusion; hence the dominant clinical features of haemolytic anaemia and painful crisis. The clinical manifestation of SCA varies, ranging from mild clinical disease diagnosed incidentally to very severe debilitating disease. Individuals with HbSS disease can be in relatively good health termed ‘steady state’ or present with acute exacerbation of symptoms termed ‘crisis’ or can present with chronic complications manifesting in virtually all systems in the body such as the brain, skeletal system and the kidneys.

Involvement of the kidneys by sickle cell anaemia is termed sickle cell nephropathy and is a well-recognised entity in sickle cell disease. The renal manifestations of sickle cell disease include hyposthenuria, haematuria due to papillary necrosis, proteinuria which can vary from microalbuminuria to nephrotic range, focal glomerulosclerosis that can lead to end-stage renal disease and renal medullary carcinoma. Sickle cell nephropathy (SCN) progresses steadily with different manifestations in various decades of life. This heterogeneity in presentation manifests in the first decade of life as decreased medullary blood flow, nocturia, enuresis, hyposthenuria and glomerular hyperfiltration; these proceed to microscopic haematuria due to renal papillary necrosis and loss of vasa recta in the second decade of life. The findings in patients in the third decade may include gross haematuria secondary to renal papillary necrosis, interstitial nephritis, membranoproliferative glomerulonephritis, decreased renal blood flow and glomerular filtration rate. Pyelonephritis, decreased uric acid clearance and hypertension starts from the fourth decade of life with eventual progression to chronic kidney disease (CKD)/end-stage renal disease.

The index study is a single centre study aimed at finding the prevalence of chronic kidney disease and at identifying its risk factors among adult patients with HbSS. The previous studies have revealed the enormous burden of CKD and SCN with varying reports of prevalence of SCN ranging from 5-18% of the total SCA population worldwide. Studies by Arogundade et al. and later by Bolarinwa et al. identified the risk factors and clinical course of SCN in South-Western Nigerian. But such study does not exist in our centre which may be different being located in Northeastern Nigeria, a region having one of the worst health care indices in the country and peculiar geographical characteristics which have been shown to affect the morbidity of SCA, which further buttress the justification for this study.

**Patients and Methods.** This was a single centre cross-sectional study carried out at University of Maiduguri teaching hospital, Borno state, northeastern Nigeria. The subjects consisted of adolescents and adults with SCA diagnosed using Hb electrophoresis at pH 8.6. Patients were recruited sequentially from the adult haematology outpatient clinic and Daycare ward of the unit from January 2013 to April 2018 (5 years period). Socio-demographic (age, sex), anthropometric (height, weight), systolic and diastolic blood pressure were recorded during a routine physical examination. Clinical variables including age at diagnosis of SCA, the frequency of vaso-occlusive crises, number of hospitalisations per annum and transfusion therapy were collected. Laboratory data including haematological profile, renal function test were also obtained. The glomerular filtration rate was estimated (eGFR) using the ‘modification of diet in renal disease’ (MDRD) formula. Proteinuria was reported as trace or 1+4+ from the dipstick. The staging of kidney disease was based on the Kidney Disease Outcome Quality Initiative (K/DOQI) recommended classification system as follows: G1: GFR >90 ml/min/1.73 m²; G2: GFR 60–89 ml/min/1.73 m²; G3a: GFR 45–59 ml/min/1.73 m²; G3b: GFR30–44, G4: GFR 15–29 ml/min/1.73 m², G5: GFR <15 ml/min/1.73 m². Albuminuria level A₁: <30mg/g, A₂: 30-300mg/g, A₃: >300mg/g. Patients who have GFR <60ml/min/1.73m² and/or albuminuria >30mg/g are considered to have chronic kidney disease. Hyperfiltration is defined as GFR >120ml/min/1.73m² and albuminuria <30mg/g in females and >130ml/min/1.73m² and albuminuria <30mg/g in males. In the current study, CKD was classified based on eGFR only.

**Statistical analysis.** Data collected were transferred into Excel (Microsoft, Seattle, WA, USA) and SPSS version 20 (IB Corp. Armonk, NY, USA). Variables were log transformed where appropriate to obtain a normal distribution. The student t-test was used for continuous variables and chi-square for categorical variable for comparisons of means and proportions amongst subgroups. Associations between continuous variables were assessed using Pearson’s correlation. For all analysis, a p-value of <0.05 was considered significant.

**Results.**

**Clinical and laboratory parameters of study participants.** Two hundred and eighty-four patients were recruited during the study period, 27 (9.5%) patients were excluded from the study due to incomplete data. There were a roughly equal number of males 129 (50.2%) and females 128 (49.8%).
The clinical and laboratory parameters of the participants are shown in Table 1.

**Prevalence and various stages of CKD.** A total of 257 HbSS patients had glomerular filtration estimates available. The median serum creatinine was 106µmol/l (IQR 101) and eGFR was 120 ml/min/1.73m² (IQR 100) (Table 1). The results showed that one hundred patients (38.9%) had CKD (GFR<60ml/minute) whereas 157 (61.1%) patients had normal renal parameters. Further stratification of subjects based on eGFR showed that sixty-nine (26.8%) had hyperfiltration and 9 (3.5%) had end-stage renal disease (Table 2). The prevalence of CKD was slightly higher amongst the male patients (55%) compared to the female population (45%).

**Table 2.** Prevalence of the various stages of chronic kidney disease amongst the study participants.

| Stage | No (%) |
|-------|--------|
| G1    | 104 (40.5) |
| G2    | 53 (20.6) |
| G3a   | 33 (12.8) |
| G3b   | 28 (10.9) |
| G4    | 30 (11.7) |
| G5    | 9 (3.5) |

Association of clinical and laboratory parameters amongst patients with and without CKD. Patients with CKD were found to be older than patients with normal kidney function (p=0.000). There was no gender difference in frequency of crises (no/yr), admissions/year, total blood transfused, weight, SBP, DBP, albumin, protein, Urea, Creatinine, haematuria.

**Table 3: Comparison between patients with CKD and those with normal kidney function**

| Parameter            | Normal kidney function (n=157) | CKD (n=100) | P     |
|----------------------|--------------------------------|-------------|-------|
| Age(years)           | 22.45±5.46                     | 26.52±6.98  | 0.000*|
| Sex                  |                                |             |       |
| Male                 | 74(47.1%)                      | 55(55%)     | χ²=0.219** |
| Female               | 83(52.9%)                      | 45(45%)     |       |
| Age at diagnosis (mon)| 28.23±3.44                     | 31.37±8.62  | 0.847 |
| Frequency of crises (no/yr)| 2.82±3.44              | 2.53±2.99   | 0.536 |
| Admissions/year      | 0.90±1.47                      | 0.75±1.01   | 0.425 |
| Total blood transfused| 2.61±5.47                     | 7.91±8.68   | 0.000*|
| Weight (Kg)          | 45.32±10.85                    | 45.76±9.46  | 0.742 |
| SBP (mmHg)           | 111.51±13.15                   | 113.95±14.74| 0.179 |
| DBP (mmHg)           | 64.43±10.89                    | 67.19±12.59 | 0.071 |
| WBC (x 10^9/L)       | 10.65±3.67                     | 10.40±3.85  | 0.650 |
| Platelets (x 10^9/L) | 399.84±144.42                  | 341.91±164.57| 0.056 |
| Urea (mmol/L)        | 5.79±4.33                      | 13.45±6.35  | 0.000*|
| Creatinine (μmol/L)  | 85.13±26.63                    | 273.73±184.71| 0.000*|
| haematuria           | 39%                            | 46%         | 1.09***|
| Uric acid (mmol/L)   | 459.42±196.32                  | 637.16±242.63| 0.000*|

*significant student t-test **chi-square *** Odds ratio. SBP: Systolic blood pressure, DBP: Diastolic blood pressure, PCV: packed cell volume, WBC: white blood cell count.
variation between patients with CKD compared with those with normal kidney function (p=0.219). Also, there was no significant difference between the age of diagnosis of SCA (p=0.847), a number of vaso-occlusive crises (p=0.536) and the total number of admissions per annum (p=0.425) amongst patients with and without CKD. Similarly, the weight (p=0.742), SBP (p=0.179) and DBP (p=0.071) showed no comparable difference. In contrast to these clinical parameters, there was a significant difference in the median PCV (p=0.000), urea (p=0.000), creatinine (p=0.000) and uric acid (p=0.000) of patients with CKD compared to those without (Table 3).

**Clinical and laboratory factors affecting eGFR.** The eGFR was significantly and negatively associated with the median values for age (r -0.353, p=0.000), SBP (r -0.148, p=0.021), DBP (r -0.213, p=0.001) and total number of blood units received (r -0.276, p=0.000). The median PCV (r 0.371, p=0.000), urea (r 0.527, p=0.000), creatinine (r 0.625, p=0.000) were all positive predictors of eGFR. There was a negative correlation between eGFR and uric acid level (r -0.419, p=0.000). There was no significant association between the eGFR and clinical parameters such as patient sex, number of vaso-occlusive crises per annum and age at diagnosis of SCA; or laboratory indices such as WBC and platelets count (Table 4).

Out of 257 patients studied, 85 (33.1%) had haematuria whereas 172 (66.9%) had no haematuria. Haematuria was noted in 36 (35.0%) of the patients with GFR < 60 ml/min/1.73 m² and 49 (32.0%) of those with GFR > 60 ml/min/1.73 m² (Table 5).

**Table 4. Clinical and laboratory factors affecting eGFR**

| Variables                  | Correlation coefficient (r) | P value  |
|----------------------------|----------------------------|----------|
| **Clinical parameters**    |                            |          |
| Age (years)                | -0.353                     | 0.000*   |
| Sex                        | -0.109                     | 0.081    |
| Age at diagnosis of SCA (mon) | -0.085                     | 0.436    |
| Weight (kg)                | -0.146                     | 0.027*   |
| SBP (mmHg)                 | -0.148                     | 0.021*   |
| DBP (mmHg)                 | -0.213                     | 0.001*   |
| VOC/yr                     | 0.012                      | 0.862    |
| Total blood transfusion    | -0.276                     | 0.000*   |
| **Haematological parameters** |                           |          |
| PCV (%)                    | 0.371                      | 0.000*   |
| WBC (x 10⁹/L)              | 0.006                      | 0.931    |
| Platelets (x 10⁹/L)        | 0.146                      | 0.131    |
| **Biochemical indices**    |                            |          |
| Urea (mmol/L)              | 0.527                      | 0.000*   |
| Creatinine (µmol/l)        | 0.625                      | 0.000*   |
| Uric acid (mmol/l)         | -0.419                     | 0.000*   |

* Significant result. SBP: Systolic blood pressure, DBP: Diastolic blood pressure, PCV: packed cell volume, WBC: white blood cell count.

**Table 5. Prevalence of haematuria across the various stages of CKD.**

| Haematuria | KDIGO | Negative n(%) | Positive n(%) | Total |
|------------|-------|---------------|---------------|-------|
| G1         | 80 (76.9) | 24 (23.1) | 104 |
| G2         | 28 (52.8) | 25 (47.2) | 53 |
| G3         | 23 (69.7) | 10 (30.3) | 33 |
| G4         | 18 (64.3) | 10 (35.7) | 28 |
| G5         | 21 (70.0) | 9 (30.0) | 30 |
| G6         | 2 (22.2) | 7 (77.8) | 9 |

**Discussion.** Advances in the medical care of patients with SCA has made it possible for this individual to live longer and as such, they are confronted with long-term complications of the condition such as chronic kidney disease. This study is the first in Northeastern Nigeria to determine the prevalence of CKD amongst patients with SCA and risk factors contributing to its development. The median age of the patients in this study was similar to that found in several similar studies by Arogundade et al.16 and Bolarinwa et al.17 in South-Western Nigeria as well as Powars et al.18 The results indicate a high prevalence of CKD (38.9%) amongst the sickle cell population. This finding is similar to that obtained in the study by Arogundade et al.;16 however, this is higher than the prevalence of CKD in the non-sickle cell population in Nigeria,23,24 indicating an additional impact of HbSS on the prevalence of kidney disease.

The prevalence of glomerular hyperfiltration of 26.8% was comparable to the previous study by Bolarinwa from South Western Nigeria; but differ with previous occurrence rates in reports from other parts of the world.25,26,27 Hyperfiltration is an early marker of renal dysfunction, with an increased risk of progression into CKD and ESRD.11,28 Vazquez et al26 have found increased levels of nephrin in the urine of HbSS patients with persistent hyperfiltration suggests that glomerular damage is caused by hyperfiltration. Future research on this group of patients could lead to the discovery of useful interventions that can prevent the progression into sickle cell nephropathy. About one-third of our patient’s population belonged to the category of early stage renal disease (34% combined rates for stages 1 and 2 CKD), in contrast to 66.7%17 88.8%28 and 53%30 rates previously observed. The British guideline on the classification of CKD recognises this group to be associated with the tendency for worsening kidney function and cardiovascular complications.31 The K/DOQI also recognises individuals in this category of renal disease to be at risk of progressive disease.32 The prevalence rates for stage 3 renal disease was 23.7%, in contrast, Bolarinwa et al. and Yusuf et al. reported lower rates of 2.7% and 9.5% respectively, and Anke et al.30 reported a higher rate of 42% from their study. Stage 3 renal disease marks a critical point in the spectrum of CKD because it represents the beginning of established
kidney disease. Identifying patients in this category is important in ensuring measures can be taken to slow the progression to more advanced stages.

Furthermore, our result showed a combined prevalence rate of 15.2% for stage 4 CKD and ESRD, in contrast to previously reported rates of 1.4% and 5% from earlier studies. However, these other studies investigated a a small number of subjects compared to our large cohort. Overall, our result shows that more than two third of our patients present with advanced stage CKD (stage 3 and above). It is possible that other yet to be identified factors may be explaining these differences, such as environmental and social factors.

The current study identified some important risk factors associated with the development of renal dysfunction. Our results replicate the previously reported positive association of eGFR with clinical parameters including age, DBP and total blood transfusion received; and with laboratory parameters, such as haematocrit, serum levels of urea, creatinine and uric acid. Recent studies by Drawz et al. has shown that age is inversely related to GFR among HbSS patients. Both age and DBP have been associated as risk factors for the development of microalbuminuria, a marker of early renal impairment. Several earlier studies have shown that anaemia correlated with GFR. An elaborate study by Saraf et al. showed that haemoglobinuria was associated with progression of CKD in SCA. However, the index study did not assess for haemoglobinuria, but the prevalence of haematuria of CKD in SCA. However, the index study did not assess for haemoglobinuria, but the prevalence of haematuria was assessed and noted to be more in patients with CKD.

Future direction and way forward. Monitoring and detection of early stages will allow for interventions which may delay progression into advanced stages and ESRD. Further studies to correlate such parameters as following up those with hyperfiltration and also studies to elucidate yet to be identified environmental, genetic or epigenetic risk factors for CKD in SCA in our region will be pursued.

Conclusions. The present study has revealed a high prevalence of CKD amongst patients with SCA in this region (38.9%; N=257). About a quarter of these patients had hyperfiltration, while more than two-third had advanced stage CKD (stage 3 and above). Age, SBP and DBP, total blood transfusion were important clinical predictors of eGFR; while haematocrit, urea, creatinine and uric acid levels significantly predicted eGFR.

References:

1. Weatherall DJ. Genetic disorders of haemoglobin. In: Hoffbrand AV, Lewis SM, Tuddenham EGD (eds). Postgraduate Haematology 4th edition. Great Britain. Butterworth-Heinemann, 1999: 91-119.
2. Eaton WA, Hofrichter J. Sickle haemoglobin polymerization. Adv Protein Chem. 1990; 40:63. https://doi.org/10.1016/S0065-3233(08)60287-9
3. Beutler E. The sickle cell diseases and related problems. In: Williams JW, Beutler E, Ersliev AJ, Lichtman M (eds). Haematology 4th edition. New York: McGraw- Hill, 1990: 613-644.
4. Noguchi CT, Schechter AN. Sickle haemoglobin polymerization in solution and in cells. Annual Review of Biophysics and Biophysical chemistry. 1985; 14: 239-263 https://doi.org/10.1146/annurev.bb.14.060185.001323 PMid:3890882
5. Mohandas N, Ross ME, Clark MR. Association between morphologic distortion of sickle cells and deoxygenation- induced cation permeability increase. Blood, 1986; 68 (2): 450-454 PMid:3730609
6. Lew VL, Eizizon Z, Bookchin RM. Dehydration response of sickle cells to sickling- induced Ca++ permeabilization. Blood. 2002; 99(7): 2578-2585. https://doi.org/10.1182/blood.V99.7.2578 PMid:11895796
7. Akinola NO, Stevens ME, Franklin IM, Nash GB, Stuart J. Rheological changes in the prodromal and established phases of sickle cell vaso-occlusive crisis. British Journal of Haematology, 1992, 81: 598-602. https://doi.org/10.1111/j.1365-2141.1992.tb00998.x PMid:1390248
8. Bookchin RM, Lew VL. Pathophysiology of sickle cell anaemia. Haematology/ Oncology Clinic of North America. 1996; 10 (6): 1241-1254. https://doi.org/10.1016/S1089-8588(05)70397-X
9. Flemming AF. The presentation, management and prevention of crises in sickle-cell disease in Africa. Blood rev. 1989; 31: 18–28. https://doi.org/10.1016/0768-960X(89)90022-2
10. Bainbridge R, Higgs DR, Maude GH, Serjeant GR. Clinical presentation of homozygous sickle cell disease. J pedtr. 1985; 106: 881. https://doi.org/10.1016/S0003-4819(85)80230-4
11. Serjeant GR. Sickle cell disease. Oxford. Oxford University Press. 1992; 261.
12. Akinsola W, Odesanmi WO, Ogumuyi JO, and Ladipo GOA. Diseases causing chronic renal failure in Nigerians- a prospective study of 100 cases. Afr J Med Sci. 1989; 18(2): 131–137.
13. Ulasi II, Ijomah CK. The enormity of chronic kidney disease in Nigeria: The situation in a teaching hospital in south east Nigeria. Journal of Tropical Medicine. 2010 https://doi.org/10.1155/2010/501957 PMid:20613945 PMCID:PMC2898835
14. Pham PT, Pham PC, Wilkinson AH, Lew SQ. Renal abnormalities in sickle cell disease. Kidney Int. 2000; 57: i. https://doi.org/10.1046/j.1523-1755.2000.00806.x PMid:10620819
15. Saborio P, Scheinman JL. Sickle cell Nephropathy. J Am Soc Nephrol. 1999; 10: 187- 192. PMid:9890326
16. Arogundade FA, Sanusi AA, Hassan MO, Salawu L, Durosimi MA, Akinsola A (2010). An appraisal of renal dysfunction and its risk factors in patients with sickle cell disease. Nephron. Clin. Pract. 118: 225-231. https://doi.org/10.1159/000321138 PMid:21196767
17. Bolanrina RA, Akinladje KS, Kuti M et al. Renal disease in adult Nigerians with sickle cell anemia: a report of prevalence, clinical features and risk factors. Saudi J Kidney Dis. Transpl 2012, 23:171-175.PMid:22237246
18. Powars DR, Elliot-Mills DD, Chan L, Hiti AL, Opas LM, Johnson C: chronic renal failure in sickle cell disease: Risk factors, clinical course and mortality. Ann Intern Med 115: 614-620. https://doi.org/10.7326/0003-4819-115-8-614 PMid:1892333
19. National Population Commission Federal republic of Nigeria. Nigeria
Demographic and Health survey preliminary report. Calverton, Maryland, USA. Measure DHS, ICF macro, 2008; 17:24.

20. Ahmed SG, Kagbu MB, Abjah UA, Bukar AA. (2012) Seasonal variations in the frequencies of acute vaso-occlusive Morbidities among sickle cell anaemia and patients in Northern Nigeria. Journal of Blood disorders and Transfusion. 01/2012; 3(120).

21. Levey AS, Bosch J, Lewis J, Greene T, Rogers N and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal disease study group. Annals of internal medicine, 1999, 130, 461-470. https://doi.org/10.7326/0003-4819-130-6-199903160-00002 PMid:10075613

22. K/DOQI: Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:51-S266. PMid:11904577

23. Wachukwu CM, Emem-Chioma PC, Wokoma FS, Oko-Jaja RI. Prevalence of risk factors for chronic kidney disease among adults in a university community in southern Nigeria. Pan African Medical Journal. 2015; 21:120 doi:10.11604/pamj.2015.21.120.7079 https://doi.org/10.11604/pamj.2015.21.120.7079

24. Egbi OG, Okafor UH, Miebodei KE, Kasia BE, Kunle-Olowu OE, Unuigbe EI. Prevalence and correlates of chronic kidney disease among civil servants in Bayelsa state, Nigeria. Niger J Clin Pract 2014;17:602-7. https://doi.org/10.4103/1119-3077.141426 PMid:25244271

25. Geard A, Pulé GD, Chemegni BC, Bitoungui VJN, Kengne AP, Chimusa ER et al. Clinical and genetic predictors of renal dysfunction in sickle cell anaemia in Cameroon. British Journal of Haematology, 2017; 178 : 629-639 https://doi.org/10.1111/bjh.14724 PMid:28466968 PMCid:PMC5669286

26. Vazquez B, Shah B, Zhang X, Lash J P, Gordeuk V R, Saraf S L. Hyperfiltration is Associated with Microalbuminuria in Patients with Sickle Cell Anemia. Am J Hematol. 2014 December; 89(12): 1156-1157. https://doi.org/10.1002/ajh.23817 PMid:25132221 PMCid:PMC4237621

27. Aloni MN, Ngulu RM, Gini-Ehungu JL, Nsibu CN, Ekila MB and Lepira FB. Renal function in children suffering from sickle cell disease: challenge of early detection in highly resource-scarce settings. PLoS ONE, 2014;9,1-5. https://doi.org/10.1371/journal.pone.0096561 PMid:24810610 PMCid:PMC4014510

28. Al Ladu, AM Abba; 2017. A Review of Prevalence, Risk Factors and Clinical Significance of Microalbuminuria in Patients with Sickle Cell Anaemia. Sokoto Journal of Medical Laboratory Science, 2(2): 141 – 145

29. Yusuf R, Hassan A, Ibrahim IN, Babadoko AA, Ibinaie PO. Assessment of kidney function in sickle cell anemia patients in Zaria, Nigeria. Sahel Med J 2017; 20:21-5.

30. Aneke JC, Adegoke AO, Oyekunle AA, Oshe PO, Sanusi AA and Okocha EC et al. Degrees of Kidney Disease in Nigerian Adults with Sickle-Cell Disease. Med Princ Pract 2014;23:271-274 https://doi.org/10.1159/000361029 PMid:24751459 PMCid:PMC5586881

31. Clinical guideline 73: Chronic Kidney Disease. London, National Institute for Health and Clinical Excellence, 2008, pp.4.

32. Drawz P, Ayyappan S, Nouraie M, Saraf S, Gordeuk V, Hostetter T, Gladwin M T, Little J. Kidney Disease among Patients with Sickle Cell Disease, Hemoglobin SS and SC. Clin J Am Soc Neph 2015 Feb 5; 11(2): 207-215. https://doi.org/10.2215/CJN.03940415 PMid:26672090 PMCid:PMC4741034

33. Saraf SL, Zhang X, Kania T, Lash JP et al. Haemoglobinuria is associated with chronic kidney disease and its progression in patients with sickle cell anemia. (2014): 165 (5): 729- 739.